Form 4: Geno J. Germano, Director at Precision BioSciences, Acquires Restricted Stock Units

Director Geno J. Germano acquired 9,826 Restricted Stock Units (RSUs) of Precision BioSciences, Inc. on June 4, 2024, which will vest on the earlier of June 4, 2025, or the day before the next annual meeting, subject to continued service.

Summary

• On June 4, 2024, Geno J. Germano, a director at Precision BioSciences, Inc. (DTIL), acquired 9,826 Restricted Stock Units (RSUs).
• Each RSU represents the right to receive one share of Precision BioSciences' common stock or an equivalent cash amount.
• The RSUs will vest on the earlier of June 4, 2025, or the day immediately prior to the company's next annual meeting of stockholders, contingent upon Germano's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider transactions. The acquisition of RSUs can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service to the company, aligning his interests with those of the shareholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of RSUs, a common form of equity compensation.

Stakeholder Impact

• The acquisition of RSUs by a director can be viewed positively by shareholders as it aligns management's interests with the company's long-term success.

Key Dates